Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187005 · ClinicalTrials.gov registry record · Phase 3
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT00187005 is a Phase 3 study that was terminated before completion, run by St. Jude Children's Research Hospital. The registered enrollment target is 53 participants.
The verdict
NCT00187005, a Phase 3 study, was terminated before completion, sponsored by St. Jude Children's Research Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.
Interventions
- DRUG Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
- DRUG L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 1998-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00187005
The ClinicalTrials.gov registry entry for NCT00187005 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase is the first listed.
NCT00187005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00187005 about?
NCT00187005 is a clinical study titled "Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia". The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-direct...
What is the current status of trial NCT00187005?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 1998-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00187005?
The interventions under investigation include: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase (DRUG), L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine (DRUG).
Who is sponsoring clinical trial NCT00187005?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.